CMV-specific TTCR-C4

CMV-specific TTCR-C4 is an adoptive cell therapy in which donor-derived T cells, specific to human cytomegalovirus (CMV), are genetically engineered to express a high-affinity T-cell receptor (TCR-C4) targeting Wilms Tumor Antigen 1 (WT1). These modified T cells are designed to provide both antiviral and antitumor activity, primarily for patients with relapsed or refractory acute myeloid leukemia (AML) following allogeneic hematopoietic cell transplantation. The mechanism combines the virus-specific cytotoxic response (to CMV) with targeted anti-leukemic activity via recognition of WT1, a tumor-associated antigen. In clinical studies, the persistence and efficacy of these cells have been variable; while infusions are well tolerated, CMV-specific TTCR-C4 showed limited lasting effectiveness, with a tendency toward terminal differentiation resembling natural killer-like phenotypes rather than the classical exhaustion observed in solid tumor-targeted T cell therapies. The construct is part of a broader investigational platform combining TCR engineering with virus-specific memory T cells for enhanced post-transplant immunotherapy[1][4][6].

Other names

CMV TTCR-C4CMV-specific T TCR-C4